 I. To estimate the toxicity, second complete response CR2 rate at the end of Block 1 therapy, and 4-month event-free survival EFS for pediatric and young adult patients with relapsed acute lymphoblastic leukemia ALL treated with bortezomib in combination with intensive re-induction chemotherapy. 